What’s the Difference Between Oral Progesterone and Suppositories?

Oral progesterone and vaginal progesterone suppositories contain the same hormone, but they behave very differently once inside your body. The oral form is swallowed, passes through your liver, and gets heavily metabolized before reaching its target tissues. A vaginal suppository bypasses the liver entirely and delivers progesterone more directly to the uterus, producing tissue concentrations that can exceed those achieved by oral dosing by a factor of ten or more, even when blood levels are lower. These pharmacological differences shape everything from side effects to which clinical situations each route works best in.

How Your Body Handles Each Route

When you swallow a progesterone capsule, it travels through your digestive tract and into the liver before entering general circulation. The liver clears progesterone rapidly, with a half-life of under three minutes in human liver tissue, meaning the hormone is broken down almost as fast as it arrives.¹ This “first-pass” metabolism is why oral progesterone has low and highly variable bioavailability. To compensate, manufacturers micronize the progesterone particles to less than 10 micrometers and suspend them in oil inside a gelatin capsule, which improves intestinal absorption enough to make oral dosing viable.²

A vaginal suppository takes a completely different path. Progesterone is absorbed through the vaginal mucosa and enters the pelvic blood supply, largely skipping the liver. Researchers have described a “first uterine pass effect” in which progesterone travels directly from the vagina to the uterus. After vaginal administration, uterine tissue levels can be more than ten times higher than those achieved by an equivalent systemic dose, even though blood levels from the vaginal route are often much lower.³ In practical terms, vaginal progesterone produces lower peaks in your bloodstream but concentrates the hormone right where it is often needed most.

A pharmacokinetic study comparing the two routes found that oral administration produced peak blood levels within about two hours, while vaginal delivery took closer to eight hours to peak. Despite that timing difference, the total amount of progesterone absorbed over 24 hours was not significantly different between the two routes, though individual variation was considerable in both cases.⁴ So the routes deliver roughly comparable total drug, but in very different patterns: oral gives a sharp spike and rapid decline, vaginal gives a slow, steady rise with high local tissue delivery.

Why Oral Progesterone Makes You Sleepy and Vaginal Mostly Doesn’t

One of the most noticeable practical differences between the two routes is drowsiness. When progesterone passes through the liver, it gets converted into metabolites, the most important being allopregnanolone. This metabolite is a powerful activator of GABA receptors in the brain, which are the same receptors targeted by sedatives and anti-anxiety drugs. A study giving women 400 mg of oral progesterone found measurable sedation and slowed eye movements compared to placebo, effects attributed to the surge of allopregnanolone produced by liver metabolism.⁵ A separate study confirmed that progesterone and its metabolites produce sedative-like effects in both men and women, though the effects were described as modest.⁶

This is why doctors typically tell you to take oral progesterone at bedtime. For some people, the drowsiness is actually welcome, especially if they have trouble sleeping. But if you need to take progesterone during the day, the sedation can be disruptive. Vaginal progesterone produces far less allopregnanolone because it largely bypasses the liver, making daytime drowsiness much less of a concern. That said, vaginal progesterone isn’t free of side effects. In a survey of women using vaginal progesterone during fertility treatment, about 57% reported vaginal wetness, nearly 40% reported the sensation of the drug leaking out, and roughly 30% experienced incomplete drug absorption or clumping.⁷ About one in five women also reported vaginal itching or perineal irritation.⁸

So the tradeoff is real: oral progesterone tends toward brain-related side effects like drowsiness and sometimes dizziness, while vaginal progesterone tends toward local discomfort and messiness. Neither is side-effect-free, and which set of issues is more tolerable depends on your life and your preferences.

Food and Oral Progesterone Absorption

If you take oral progesterone, when and what you eat matters a surprising amount. A study in postmenopausal women found that eating a high-fat meal alongside oral progesterone led to a roughly 22-fold higher peak blood concentration and a 7-fold increase in total drug exposure compared to taking the capsule on an empty stomach.⁹ An earlier study similarly showed that food increased both peak concentration and total absorption.¹⁰

This is a bigger deal than it might sound. A 22-fold swing in peak levels based on whether you had dinner first means your actual dose can vary enormously day to day depending on your eating habits. It also helps explain why oral progesterone blood levels are so variable from person to person. If your doctor prescribes oral progesterone, ask whether you should take it with food or on an empty stomach, since the answer depends on what blood level they are trying to achieve and whether the sedation from higher levels is desirable (for instance, at bedtime). Vaginal progesterone absorption isn’t affected by meals at all, which is one less variable to worry about.

Fertility Treatment and IVF

One of the most common uses for both formulations is luteal phase support during IVF cycles. After an embryo is transferred, your body needs adequate progesterone to prepare and maintain the uterine lining. For decades, vaginal progesterone has been the default choice for this, partly because of the first uterine pass effect and partly out of clinical habit.

Recent trials have challenged the assumption that vaginal is necessarily better for IVF outcomes. A large multicenter trial found that the ongoing pregnancy rate with oral micronized progesterone at 400 mg per day was statistically non-inferior to vaginal progesterone gel, with ongoing pregnancy rates of about 35% and 38% respectively.¹¹ Another randomized trial found no significant differences in clinical pregnancy, live birth, or miscarriage rates depending on whether progesterone was given orally or vaginally before embryo transfer, though blood progesterone levels were significantly higher in the oral group.¹²

Patient preference often tips the balance. Research on dydrogesterone (an oral progesterone derivative) found that patients usually prefer oral preparations over vaginal ones, citing convenience and comfort.¹³ Cultural barriers also play a role in some settings, where vaginal insertion is less acceptable. If clinical outcomes are similar, the route that patients are most likely to use consistently may be the better practical choice.

Preventing Preterm Birth

Vaginal progesterone has strong evidence for one specific obstetric use where oral progesterone has not been established: preventing preterm birth in women with a short cervix. A multicenter trial found that vaginal progesterone gel cut the rate of delivery before 33 weeks nearly in half compared to placebo (about 9% vs. 16%) in women with a cervical length between 10 and 20 millimeters on ultrasound.¹⁴ The effect held across multiple gestational-age thresholds, including delivery before 28 and 35 weeks.

A systematic review comparing vaginal progesterone to cervical cerclage (a surgical stitch placed around the cervix) found no significant difference between the two approaches for preventing preterm birth before 32 weeks or for reducing serious newborn complications.¹⁵ For many women, a daily vaginal suppository is far more appealing than a surgical procedure, so vaginal progesterone has become a first-line option in this situation. The reason oral progesterone hasn’t gained traction here likely relates to the first uterine pass effect: the cervix and uterus are the targets, and vaginal delivery puts the drug closer to those tissues.

Threatened Miscarriage in Early Pregnancy

Both routes are prescribed for early-pregnancy bleeding (threatened miscarriage), though the evidence is somewhat fragmented. A randomized trial comparing oral to vaginal micronized progesterone found that about 92% of women in the oral group continued their pregnancies, versus about 74% in the vaginal group, a statistically significant difference favoring oral administration.¹⁶ A separate trial reported similar numbers, with oral progesterone showing higher efficacy in preventing blood loss and continuing the pregnancy beyond 20 weeks.¹⁷

A meta-analysis looking at oral dydrogesterone versus vaginal micronized progesterone in women with threatened miscarriage or recurrent pregnancy loss found that oral dydrogesterone was associated with higher pregnancy continuation rates, though the overall certainty of evidence was rated low. Late pregnancy outcomes appeared similar between routes.¹⁸ The evidence here is worth treating cautiously: the individual trials are relatively small, and oral dydrogesterone is a synthetic derivative, not identical to micronized progesterone. Still, the overall trend suggests oral progesterone is at least as effective as vaginal for early pregnancy support, and possibly modestly better in this specific context.

Menopause Hormone Therapy and Endometrial Protection

For women taking estrogen as part of menopause hormone therapy, progesterone is added to protect the uterine lining from overgrowth that could lead to endometrial cancer. Both routes work here, but the dosing details differ. A systematic review by an international expert panel found that oral micronized progesterone at 200 mg per day, taken for 12 to 14 days per month (sequential dosing), provides endometrial protection for up to five years. Vaginal micronized progesterone can also protect the endometrium, but the panel noted it’s used off-label for this purpose, at doses of 45 mg daily for at least 10 days per month or 100 mg every other day.¹⁹ A separate review confirmed that 100 mg oral daily (for continuous use), 200 mg oral sequentially, or 100 mg vaginal every other day all effectively protect the endometrium.²⁰

One practical note: the panel specifically found that transdermal progesterone (creams applied to the skin) does not provide adequate endometrial protection. This is a common point of confusion because progesterone creams are widely sold over the counter. If you have a uterus and are taking estrogen for menopausal symptoms, skin creams are not a substitute for oral or vaginal progesterone as far as endometrial safety goes.

Lipid and Cardiovascular Considerations

When progesterone passes through the liver, it has opportunities to interact with metabolic processes that vaginal progesterone largely avoids. Research on how each route affects cholesterol and cardiovascular markers has been reassuring overall but does show some differences. A study of postmenopausal women found that vaginal progesterone was associated with a significant decrease in total cholesterol (about 8%) by the end of the trial, with no adverse changes in HDL cholesterol or triglycerides.²¹ Another trial found that adding oral micronized progesterone to estrogen therapy did not negatively affect blood pressure, glucose, insulin, HDL, triglycerides, or inflammatory markers. LDL cholesterol actually dropped when progesterone was added to estrogen.²²

Neither route appears to cause the negative lipid changes sometimes seen with synthetic progestins. This is one of the reasons micronized progesterone (whether oral or vaginal) has become preferred over older synthetic alternatives for menopausal hormone therapy. The cardiovascular differences between oral and vaginal micronized progesterone are small enough that they rarely drive the choice of route on their own.

The Rectal Route as a Third Option

Some women can’t or prefer not to use vaginal suppositories, whether because of vaginal bleeding, infection, discomfort, or cultural reasons. Rectal administration is a viable alternative that gets much less attention. A randomized trial comparing vaginal and rectal progesterone pessaries for IVF luteal phase support found that rectal administration was effective and well accepted.²³ A separate trial confirmed that clinical outcomes were similar between the two routes.²⁴ Like vaginal delivery, rectal absorption bypasses the liver, so the pharmacokinetic profile is more similar to vaginal than to oral. It’s worth asking about if the vaginal route isn’t working for you.

How Formulations Actually Differ at the Pharmacy

When your doctor writes a prescription, the choice of route determines not just the drug’s path through your body but often the specific product you receive. Oral micronized progesterone typically comes as oil-filled gelatin capsules (brand names vary by country). Vaginal preparations include gel applicators, soft capsules designed for insertion, and waxy suppositories (pessaries). Some capsules marketed for oral use can also be used vaginally and vice versa, though this is an off-label use in some jurisdictions. A pharmacokinetic comparison of two types of micronized progesterone capsules found meaningful differences in blood levels depending on both the formulation and route, with one brand producing roughly double the total drug exposure of another by the vaginal route.²⁵ The takeaway for patients is that switching brands or switching between oral and vaginal use of the same capsule isn’t always interchangeable, even if the active ingredient is identical.

Dydrogesterone, mentioned earlier, is a related but distinct molecule. It’s a synthetic analog of progesterone available only as an oral tablet, and it doesn’t produce the same sedative metabolites that natural progesterone does. It’s increasingly used in fertility treatment in some parts of the world as an alternative to vaginal micronized progesterone, though it isn’t available everywhere and isn’t the same drug as micronized progesterone in a strict pharmacological sense.

Choosing Between the Two in Practice

The question of which route is “better” doesn’t have a single answer because it depends on what the progesterone is being used for. For preventing preterm birth in women with a short cervix, vaginal progesterone has the strongest direct evidence and the advantage of concentrating the drug near the cervix. For IVF luteal phase support, recent trials suggest oral and vaginal routes produce similar pregnancy rates, making convenience and tolerability legitimate tiebreakers. For endometrial protection during menopause hormone therapy, oral progesterone has the more established track record and clearer dosing guidelines, though vaginal progesterone can work with careful dosing. For threatened miscarriage, the limited data slightly favor oral administration, though the evidence base is still thin.

Side effects divide along predictable lines. If drowsiness is a problem or you need to take progesterone during waking hours, vaginal may be preferable. If vaginal discharge, irritation, or the general inconvenience of insertion is a dealbreaker, oral taken at bedtime may be the better fit. And if neither oral nor vaginal works well for you, the rectal route is an underappreciated option worth discussing with your provider. The most important thing is consistent use at the right dose for your clinical situation, because the biggest risk with any route is missing doses or using the wrong amount.